Accessibility Menu
Perspective Therapeutics logo

Perspective Therapeutics(NYSEMKT) CATX

Current Price$2.99
Market Cap$333.01MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2005)-71%
5 Year-60%
1 Year-30%
1 Month-1%
Perspective Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 2.922026-07-20
Perspective Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-5.5%USD 3.092026-07-13
1 month-1.02%USD 2.952026-06-18
3 month-37.07%USD 4.642026-04-21
Year to date+6.18%USD 2.752025-12-31
1 year-30.48%USD 4.202025-07-18
3 year-53.53%USD 6.282023-07-21
5 year-60%USD 7.302021-07-21
Since inception-70.8%USD 10.002005-08-18

Perspective Therapeutics Financials at a Glance

Market Cap

$333.01MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$618.00K

Net Income (TTM)

-$111.13M

EPS (TTM)

-$1.40

P/E Ratio

-2.09

Dividend

$0.00

Beta (Volatility)

1.23 (Average)

Price

$2.99

Volume

37,945

Open

$2.95

Previous Close

$2.92

Daily Range

$2.92 - $3.02

52-Week Range

$1.96 - $6.16

Estimated Earnings Date

Aug 12, 2026

CATX News

Foolcom-Featured.png

Perspective Therapeutics Reports Q2 Loss

Motley Fool Markets TeamAug 13, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Perspective Therapeutics

Perspective Therapeutics develops targeted cancer treatments using radioactive isotopes. Its therapies aim to deliver precise radiation to tumors, reducing harm to healthy tissue. The company’s products help patients with hard-to-treat cancers by offering new therapy options.

Products and Services

  • Targeted Alpha Therapies: Delivers focused radiation to cancer cells using Lead-212; no product sales revenue in 2025.
  • Imaging Diagnostics: Uses Lead-203 for cancer imaging to guide treatment decisions; revenue not material in 2025.
  • Pre-targeting Theranostic Platform: Early-stage system for antibody-based delivery of radioactive drugs; no commercial revenue yet.
  • Royalties from Brachytherapy Seeds: Earns royalties after selling its Cesium-131 seed business in 2024; $0.2 million in Q2 2025.
  • Grant Revenue: Receives research grants; $884,000 in 2025, down 39% from 2024.

Growth and Expansion

  • Divested brachytherapy business to GT Medical in April 2024, shifting focus to radiopharmaceuticals.
  • Entered exclusive option and investment agreements with Lantheus Holdings in January 2024, securing $28 million upfront.
  • Acquired and upgraded manufacturing sites in Somerset, NJ, and purchased facilities in Houston, Chicago, and Los Angeles in 2024.
  • Signed a €49 million equipment agreement with Comecer SpA in 2024 to expand manufacturing capacity.
  • Raised over $400 million in equity financings between 2024 and 2026 to fund clinical and manufacturing growth.

What Makes Perspective Therapeutics Stand Out

Perspective Therapeutics combines therapy and imaging in one platform, allowing for personalized cancer treatment. The company controls key manufacturing steps and holds patents extending into the 2040s. Its U.S.-based operations reduce exposure to currency and supply chain risks.

Five Things You Need to Know

  • Grant revenue was $884,000 in FY2025, down 39% from FY2024.
  • Operating loss was $113.6 million in FY2025, up 25% from FY2024.
  • Cash, equivalents, and short-term investments totaled $144.7 million at December 31, 2025.
  • All product sales revenue now comes from royalties after divesting brachytherapy in 2024.
  • Research and development expenses rose 104% to $84.2 million in FY2025.

Bottom Line

Perspective Therapeutics has shifted from selling cancer implants to developing targeted radiopharmaceuticals. The company invests heavily in research, manufacturing, and partnerships to advance new cancer therapies.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

166

CEO

Johan M. Spoor, MBA

Website

perspectivetherapeutics.com

Headquarters

Seattle, WA 99354, US

CATX Financials

Key Financial Metrics (TTM)

Gross Margin

-489.81%

Operating Margin

-19419.58%

Net Income Margin

-17982.69%

Return on Equity

-41.84%

Return on Capital

-54.01%

Return on Assets

-27.05%

Earnings Yield

-47.85%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$333.01MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

114.05M

Volume

37.95K

Avg. Volume

1.85M

Financials (TTM)

Gross Profit

-$3.03M

Operating Income

-$120.01M

EBITDA

-$110.64M

Operating Cash Flow

-$92.37M

Capital Expenditure

-$14.95M

Free Cash Flow

-$107.32M

Cash & ST Invst.

$270.93M

Total Debt

$4.23M

Perspective Therapeutics Performance Analysis

Perspective Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30USD 10,795,000N/A
20232023-12-31USD 1,434,000-86.7%
20242024-12-31USD 1,454,0001.4%
20252025-12-31USD 884,000-39.2%
Perspective Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-15.2%
Q32025-09-30-27.9%
Q42025-12-31-79.4%
Q12026-03-3176.7%
Perspective Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30USD -0.51N/A
20232023-12-31USD -1.74239.3%
20242024-12-31USD -1.23-29.2%
20252025-12-31USD -1.4013.5%
Perspective Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-20.0%
Q32025-09-30-16.7%
Q42025-12-31-45.7%
Q12026-03-31-4856.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$76.00K

-77.8%

Gross Profit

-$1.05M

-169.2%

Gross Margin

-13.82%

N/A

Market Cap

$333.01MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.01M

N/A

Employees

166

N/A

Net Income

-$26.19M

-44.1%

EBITDA

-$27.16M

-56.8%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$270.93M

+28.0%

Total Debt

$4.23M

+10.8%

Accounts Receivable

$58.00K

-25.6%

Inventory

$0.00

N/A

Long Term Debt

$3.11M

+11.5%

Short Term Debt

$1.13M

+8.9%

Return on Assets

-27.05%

N/A

Return on Invested Capital

-31.64%

N/A

Free Cash Flow

-$38.33M

-46.1%

Operating Cash Flow

-$31.47M

-45.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
AVRAnteris Technologies Global Corp.
$8.11-1.34%
PROFProfound Medical Corp.
$6.89+1.17%
IVVDInvivyd, Inc.
$0.68-0.95%
TLSITriSalus Life Sciences, Inc.
$4.35+0.93%

Trending Stocks

Symbol / CompanyPricePrice Chg
MARAMara Holdings
$12.32+0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$11.32+0.06%
TET1 Energy Inc.
$6.14+0.02%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$40.27-0.06%

Questions About CATX

What is the current price of Perspective Therapeutics?

Perspective Therapeutics is trading at $2.99 per share.

What is the 52-week range for Perspective Therapeutics?

Over the past 52 weeks, Perspective Therapeutics has traded between $1.96 and $6.16.

How much debt does Perspective Therapeutics have?

As of the most recent reporting period, Perspective Therapeutics reported total debt of $4.23M.

How much cash does Perspective Therapeutics have on hand?

Perspective Therapeutics reported $53.97M in cash and cash equivalents in its most recent financial results.

What is Perspective Therapeutics’s dividend yield?

Perspective Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services